CHIPNCT07511582
Corticosteroids in Hyperinflammatory Phenotype of Critical Illness
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria shortened, about 111 words Show 4 more changesShow less
- Trial sites expanded: 1 → 11 locations
- Secondary endpoints: details revised at 2 of 3 entries
- Study description expanded, about 162 words
- Publications: details revised at 40 of 40 entries
- Notable Recruitment opened
- Study completion pushed from Apr 1, 2028 to Jun 1, 2028
- Start date changed from estimate of Apr 1, 2026 to Apr 15, 2026
- Site details revised
- Notable Primary endpoint(s) modifiedv2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Drugs: Methylprednisolone (MP), Placebo
Sites
11 sites in 1 country